Shanghai Henlius Biotech Co. Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shanghai Henlius Biotech Co. Ltd.
China's research-based pharma companies reported mixed third-quarter results for their anti-PD-1 antibodies, BTK and PARP inhibitors amid broader challenges including an ongoing government-led anti-corruption campaign.
Moving decisively but not hurriedly, Henlius is taking a two-pronged approach to join the global ADC race. The first two molecules developed via its in-licensed novel linker-payload platform have entered the clinical stage, while its own proprietary programs are seeing steady R&D progress, the Chinese firm's head of early R&D tells Scrip in an interview.
Medilink’s ADC platform, which addresses the antibody endocytosis process, has received its first endorsement from a major international partner in the form of BioNTech.
While there are already restrictions on the prescribing of cancer drugs in China, oncologists in the world’s second-largest pharma market are also now being expected to strictly avoid off-label use, especially of costly imported therapies from multinationals.
- Large Molecule
- Other Names / Subsidiaries
- Fosun Pharma
- Henlius Biopharmaceuticals
- Shanghai Henlius Biotech, Inc.
- Taiwan Henlix Biotech Co., Ltd.
- Hengenix Biotech
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.